Cargando…

Association between Uremic Toxin Concentrations and Bone Mineral Density after Kidney Transplantation

Although uremic osteoporosis is a component of mineral and bone disorder in chronic kidney disease, uremic toxin (UT) concentrations in patients with end-stage kidney disease and bone mineral density (BMD) changes after kidney transplantation have not previously been described. We hypothesized that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Batteux, Benjamin, Bodeau, Sandra, André, Camille, Hurtel-Lemaire, Anne-Sophie, Gras-Champel, Valérie, Desailly-Henry, Isabelle, Masmoudi, Kamel, Bennis, Youssef, Massy, Ziad A., Kamel, Saïd, Choukroun, Gabriel, Liabeuf, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696468/ https://www.ncbi.nlm.nih.gov/pubmed/33202788 http://dx.doi.org/10.3390/toxins12110715

Ejemplares similares

Potential interactions between uraemic toxins and drugs: an application in kidney transplant recipients treated with calcineurin inhibitors
por: André, Camille, et al.
Publicado: (2021)

Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilance Database (VigiBase(®))
por: Dernoncourt, Amandine, et al.
Publicado: (2022)

The Prescription of Drugs That Inhibit Organic Anion Transporters 1 or 3 Is Associated with the Plasma Accumulation of Uremic Toxins in Kidney Transplant Recipients
por: André, Camille, et al.
Publicado: (2021)

Early steroid withdrawal has a positive effect on bone in kidney transplant recipients: a propensity score study with inverse probability-of-treatment weighting
por: Batteux, Benjamin, et al.
Publicado: (2020)

N-methyl-2-pyridone-5-carboxamide (2PY)—Major Metabolite of Nicotinamide: An Update on an Old Uremic Toxin
por: Lenglet, Aurélie, et al.
Publicado: (2016)

Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins
por: Laville, Solène M., et al.
Publicado: (2021)

The AKI-to-CKD Transition: The Role of Uremic Toxins
por: André, Camille, et al.
Publicado: (2023)

Uremic Toxins and Vascular Dysfunction
por: Six, Isabelle, et al.
Publicado: (2020)

The Role of Gut-Derived, Protein-Bound Uremic Toxins in the Cardiovascular Complications of Acute Kidney Injury
por: Caillard, Pauline, et al.
Publicado: (2022)

Drugs associated with incident fragility fractures in kidney transplant recipients
por: Batteux, Benjamin, et al.
Publicado: (2022)

Risk factors for and characteristics of community‐ and hospital‐acquired drug‐induced acute kidney injuries
por: Rey, Amayelle, et al.
Publicado: (2022)

Evaluation of Changes Over Time in the Drug Burden and Medication Regimen Complexity in ESRD Patients Before and After Renal Transplantation
por: Marienne, Justine, et al.
Publicado: (2020)

Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation
por: Gaucher, Louis, et al.
Publicado: (2021)

Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors
por: Gaucher, Louis, et al.
Publicado: (2021)

Uremic Toxins and Clinical Outcomes: The Impact of Kidney Transplantation
por: Liabeuf, Sophie, et al.
Publicado: (2018)

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study
por: Rey, Amayelle, et al.
Publicado: (2019)

Protein-Bound Uremic Toxins: New Insight from Clinical Studies
por: Liabeuf, Sophie, et al.
Publicado: (2011)

The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial
por: Bennis, Youssef, et al.
Publicado: (2019)

Does P-Cresylglucuronide Have the Same Impact on Mortality as Other Protein-Bound Uremic Toxins?
por: Liabeuf, Sophie, et al.
Publicado: (2013)

Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?
por: El Chamieh, Carolla, et al.
Publicado: (2022)

The Impact of Uremic Toxins on Vascular Smooth Muscle Cell Function
por: Hénaut, Lucie, et al.
Publicado: (2018)

The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders
por: Assem, Maryam, et al.
Publicado: (2018)

Use of the Capture-Recapture Method to Estimate the Frequency of Community- and Hospital-Acquired Drug-Induced Acute Kidney Injuries in French Databases
por: Rey, Amayelle, et al.
Publicado: (2022)

From old uraemic toxins to new uraemic toxins: place of ‘omics’
por: Massy, Ziad A, et al.
Publicado: (2018)

Risk Factors for Bleeding in Hospitalized at Risk Patients With an INR of 5 or More Treated With Vitamin K Antagonists
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Adaptation and validation of an adverse drug reaction preventability score for bleeding due to vitamin K antagonists
por: Liabeuf, Sophie, et al.
Publicado: (2016)

Serum Calcification Propensity Represents a Good Biomarker of Vascular Calcification: A Systematic Review
por: Pluquet, Maxime, et al.
Publicado: (2022)

Proton-Pump Inhibitors and Serum Concentrations of Uremic Toxins in Patients with Chronic Kidney Disease
por: El Chamieh, Carolla, et al.
Publicado: (2023)

Effects of Chronic Kidney Disease and Uremic Toxins on Extracellular Vesicle Biology
por: Yaker, Linda, et al.
Publicado: (2020)

Total calcium-sensing receptor expression in circulating monocytes is increased in rheumatoid arthritis patients with severe coronary artery calcification
por: Paccou, Julien, et al.
Publicado: (2014)

The Addition of Vascular Calcification Scores to Traditional Risk Factors Improves Cardiovascular Risk Assessment in Patients with Chronic Kidney Disease
por: Liabeuf, Sophie, et al.
Publicado: (2015)

Impact of the COVID-19 outbreak on the reporting of adverse drug reactions associated with self-medication
por: Gras, M., et al.
Publicado: (2021)

Association between Free Light Chain Levels, and Disease Progression and Mortality in Chronic Kidney Disease
por: Desjardins, Lucie, et al.
Publicado: (2013)

Association between Dental Scores and Saliva Uremic Toxins
por: Rigothier, Claire, et al.
Publicado: (2023)

COVID-19 et vaccins à adénovirus : expérience française de suivi renforcé de pharmacovigilance
por: Massy, Nathalie, et al.
Publicado: (2023)

Does kidney transplantation influence a form of discrimination for antihypertensive drugs prescriptions?
por: Cheddani, Lynda, et al.
Publicado: (2021)

The Interplay between Uremic Toxins and Albumin, Membrane Transporters and Drug Interaction
por: da Cunha, Regiane Stafim, et al.
Publicado: (2022)

Estimated Glomerular Filtration Rate Is a Poor Predictor of the Concentration of Middle Molecular Weight Uremic Solutes in Chronic Kidney Disease
por: Neirynck, Nathalie, et al.
Publicado: (2012)

Effect of Sevelamer and Nicotinamide on Albumin Carbamylation in Patients with End-Stage Kidney Disease
por: Lenglet, Aurelie, et al.
Publicado: (2021)

Correlation between Saliva Levels and Serum Levels of Free Uremic Toxins in Healthy Volunteers
por: Fabresse, Nicolas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jvrd079fo5j8ocfhradlcs4b1r